Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Interim CFO | January 30, 2026 | February 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TENAX THERAPEUTICS, INC.
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.51 · Expires 2029-01-30 | Direct | 50,000 |
Reported balance
After 2026-01-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-30 · Exercise / conversion · Acquired 50,000 · Balance 50,000 F1: The options vest and become exercisable with 50% vesting January 30, 2026 and 50% vesting on May 31, 2026, subject to the Reporting Person's continuous service to the Issuer. |
| Common StockSEC Table I · non-derivative | Direct | 2,000 |
Reported balance
Holding disclosure · report date 2026-01-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 1,000 |
Reported balance
Holding disclosure · report date 2026-01-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 5,000 |
Reported balance
Holding disclosure · report date 2026-01-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable with 50% vesting January 30, 2026 and 50% vesting on May 31, 2026, subject to the Reporting Person's continuous service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Feb 3, 2026 22:57 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $12.51 | $0.00 |
DisclosureSEC source: 0001550701-26-000001 · primary_doc.xml · derivative · entry 4 MCGAULEY THOMAS · CIK 0001550701 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vest and become exercisable with 50% vesting January 30, 2026 and 50% vesting on May 31, 2026, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 00:01 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 5,000 | $7.23 | $36,140.00 |
DisclosureSEC source: 0001550701-25-000002 · primary_doc.xml · nonDerivative · entry 3 MCGAULEY THOMAS · CIK 0001550701 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 5,000 F2 · price: This transaction was executed in multiple trades at prices ranging from $7.17 to $7.30. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 00:01 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 1,000 | $7.35 | $7,350.00 |
DisclosureSEC source: 0001550701-25-000002 · primary_doc.xml · nonDerivative · entry 2 MCGAULEY THOMAS · CIK 0001550701 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By Child Disclosed balance after: 1,000 Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 00:01 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 2,000 | $7.34 | $14,674.00 |
DisclosureSEC source: 0001550701-25-000002 · primary_doc.xml · nonDerivative · entry 1 MCGAULEY THOMAS · CIK 0001550701 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $7.14 to $7.43. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.